A tale of two trials: The West of Scotland Coronary Prevention Study and the Texas Coronary Atherosclerosis Prevention Study

Atherosclerosis

Volumn 139, Issue 2, 1998, Pages 223-229

  Shepherd, James ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GEMFIBROZIL; MEVINOLIN; PLACEBO; PRAVASTATIN;

ADULT; AGED; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; FEMALE; GENE TARGETING; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; LIPID OXIDATION; MAJOR CLINICAL STUDY; MALE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW;

EID: 0031858976     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(98)00104-X     Document Type: Article

References (31)

1. McGill H.C., McMahan C.A., Malcolm G.T., Oalmann M.C., Strong J.P. Effects of serum lipoproteins and smoking on atherosclerosis in young men and women. Arterioscler Thromb Vasc Biol. 17:1997;95-106.
2. McGill H.C., Strong J.P., Tracy R.E., McMahon C.A., Oalmann M.C. Relation of a post mortem renal index of hypertension to atherosclerosis in youth. Arterioscler Thromb Vasc Biol. 15:1995;2222-2228.
3. Committee of Principal Investigators WHO Clofibrate Trial A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate: report from the Committee of Principal Investigators. Br Heart J. 40:1978;1069-1118.
4. Committee of Principal Investigators WHO Clofibrate Trial. Cooperative Trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up report. Lancet. ii:1980;379-385.
5. The Lipid Research Clinics Program The Coronary Primary Prevention Trial: design and implementation. Chron Dis. 32:1979;609-631.
6. The Lipid Research Clinics The Lipid Research Clinics Coronary Primary Prevention Trial Results. I. Reduction in incidence of coronary heart disease. J Am Med Assoc. 251:1984;351-364.
7. The Lipid Research Clinics The Lipid Research Clinics Coronary Primary Prevention Trial Results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. J Am Med Assoc. 251:1984;365-374.
8. Mantarri O., Elo O., Frick M.H.et al. The Helsinki Heart Study: basic design and randomisation procedure. Eur Heart J. 9(Suppl 1):1987;1-29.
9. Frick M.H., Elo O., Haapa K.et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. New Engl J Med. 317:1987;1237-1245.
10. Pan HY. HMG-CoA reductase inhibitors: clinical pharmacology. In: Gotto AM Jr, Mancini M, Richter WO, Schwandt P, editors. Treatment of Severe Hypercholesterolemia in the Prevention of Coronary Heart Disease. Proceedings of the 2nd International Symposium, Munich 1989, Basel: Karger, 1990:66-70.
11. Tsujita Y., Juroda M., Shimada Y., Tanzawa K., Arai M., Kaneko I., Tanaka M., Masuda H., Tarumi C., Watanabe Y.et al. CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species. Biochim Biophys Acta. 877:1986;50-60.
12. Tsujita Y., Watanabe Y. Pravastatin sodium: novel cholesterol-lowering agent that inhibits HMG-CoA Reductase. Cardiovasc Drug Rev. 7:1989;110-126.
13. Reihner E., Rudling M., Stahlberg D., Berglund L., Ewerth S., Bjorkhem I., Einarsson K., Angelin B. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase on hepatic metabolism of cholesterol. New Engl J Med. 3223:1990;244-248.
14. Singhvi S.M., Pan H.Y., Morrison R.A., Willard D.A. Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. Br J Clin Pharmacol. 29:1990;239-242.
15. Vega GL, Krauss RM, Grundy SM. Pravastatin therapy in primary moderate hypercholesterolaemia: changes in metabolism of apolipoprotein B-containing lipoproteins. J Intern Med 199;227:81-94.
16. Mosley S.T., Kalinowski S.S., Shafer B.L., Tanaka R.D. Tissue-selective acute effects of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase on cholesterol biosynthesis in the lens. J Lipid Res. 30:1989;1411-1420.
17. The West of Scotland Coronary Prevention Study Group A coronary primary prevention study of Scottish men aged 45-74 years: trial design. J Clin Epidemiol. 45:1992;849-860.
18. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., Macfarlane P.W., McKillop J.H., Packard C.J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New Engl J Med. 333:1995;1301-1307.
19. Downs J.R., Beere P.A., Whitney E., Clearfield M., Weis S., Rochen J., Stein E.A., Shapiro D.R., Langendorfer A., Gotto A.M. Design and rationale of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS). Am J Cardiol. 80:1997;287-293.
20. Alberts A.W. Discovery, biochemistry and biology of lovastatin. Am J Cardiol. 62:1988;10-15J.
21. Alberts A.W., Chen J., Juron G.et al. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci USA. 77(7):1980;3957-3961.
22. Albers-Schonberg G., Joshua H., Lopez M.B.et al. Dihydromevinolin, a potent hypocholesterolemic metabolite produced by Aspergillus terreus. J Antibiotics. 34(5):1981;507-512.
23. MacDonald J.S., Gerson R.J., Kornburst D.J.et al. Preclinical evaluations of lovastatin. Am J Cardiol. 62:1988;16-27J.
24. Henwood J.M., Heel R.C. Lovastatin, a preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidaemia. Drugs. 36:1988;429-454.
25. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Lagendorfer A, Stein EA, Kruyer W, Gotto AM. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. J Am Med Assoc 1998;279:1615-22.
26. Pyorala K., DeBacker G., Poole-Wilson P., Wood D. on behalf of the Task Force. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Atherosclerosis. 110:1994;121-161.
27. National Cholesterol Education Program Adult Treatment Panel II. Second report of the expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Circulation. 89:1994;1329-1445.
28. Garber A.M., Browner W.S., Hulley S.B. Cholesterol screening in asymptomatic adults, revisited. An Intern Med. 124:1996;518-531.
29. LaRosa J.C. Cholesterol agnostics. Ann Intern Med. 124:1996;505-508.
30. Martin M.J., Hulley S.B., Browner W.S., Kuller L.H., Wentworth D. Serum cholesterol blood pressure and mortality: implications from a cohort of 361,662 men. Lancet. ii:1986;933-936.
31. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on coronary events in the West of Scotland Coronary Prevention Study. Circulation, in press.